Creative Biolabs highlighted its comprehensive contract development and manufacturing organization (CDMO) services during the recent Scientist Solution Vendor Event, unveiling advanced capabilities in antibody production, plasmid development, and oncology therapeutics.
The company's showcase emphasized a streamlined approach to biotechnology services, featuring robust solutions in cell line development, process engineering, and specialized therapeutic innovations. A key focus was their upstream and downstream plasmid process development, which ensures high-quality, reliable production through meticulous validation workflows.
In the oncology space, Creative Biolabs demonstrated significant progress in tumor-infiltrating lymphocyte (TIL) therapy development. Their approach integrates advanced techniques including tumor resection, lymphocyte isolation, and expansion using sophisticated rapid expansion protocols. These methods leverage monoclonal antibodies, feeder cell technology, and cytokine support to cultivate patient-specific therapeutic lymphocytes.
The company is also preparing for an upcoming gene therapy webinar featuring expert discussions on cutting-edge technologies, including programmable gene editing, cellular perturbation technologies, and artificial intelligence applications in protein evolution.
With a robust 2025 event calendar that includes prestigious conferences such as the NIH Spring Research Vendor Fair and World Bispecific Summit, Creative Biolabs continues to position itself at the forefront of precision medicine and biotechnological innovation.
